<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01813786</url>
  </required_header>
  <id_info>
    <org_study_id>CYN12-PICO-CAPHST-07</org_study_id>
    <nct_id>NCT01813786</nct_id>
  </id_info>
  <brief_title>Clinical and Histological Evaluation of the 755nm Alexandrite Laser With Handpiece for the Treatment of Scars</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cynosure, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cynosure, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Compare efficacy and safety of handpieces on the 755nm Alexandrite laser for the treatment of&#xD;
      scars.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Device Feasibility</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Subject Biopsy Sampling</measure>
    <time_frame>3 months post last treatment</time_frame>
    <description>Histological examination of tissue samples will be compared between baseline and 3 months post treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Photographic evaluation as a measure of improvement.</measure>
    <time_frame>up to 3 months post last treatment</time_frame>
    <description>2D photographs to be taken at each visit and assessed at the end of the study by 2-3 blinded assessors for improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Biopsy Sampling</measure>
    <time_frame>2 weeks post treatment</time_frame>
    <description>Histological examination of tissue samples will be compared between baseline and 2 weeks post treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Biopsy Sampling</measure>
    <time_frame>1 month post treatment</time_frame>
    <description>Histological examination of tissue samples will be compared between baseline and 1 month post treatment.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of participants with adverse events as a measure of safety and tolerability</measure>
    <time_frame>up to 3 months post last treatment</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Scars</condition>
  <arm_group>
    <arm_group_label>755nm Alexandrite Laser with Handpiece 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Focusing energy on skin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>755nm Alexandrite Laser with handpiece 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Focusing energy on skin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>755nm Alexandrite laser with handpiece 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Focusing energy on skin</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>755nm Alexandrite Laser with handpiece 2</intervention_name>
    <description>Focusing energy on skin</description>
    <arm_group_label>755nm Alexandrite Laser with Handpiece 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>755nm Alexandrite Laser with handpiece 1</intervention_name>
    <description>focusing energy at skin surface</description>
    <arm_group_label>755nm Alexandrite laser with handpiece 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>755nm Alexandrite Laser with handpiece 3</intervention_name>
    <description>Focusing energy on skin</description>
    <arm_group_label>755nm Alexandrite Laser with handpiece 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Is a healthy male or female between 18 and 85 years old&#xD;
&#xD;
          2. Has unwanted scars not including atrophic scars and wishes to undergo laser&#xD;
             treatments.&#xD;
&#xD;
          3. Is willing to consent to participate in the study.&#xD;
&#xD;
          4. Is willing to comply with all requirements of the study including biopsies, being&#xD;
             photographed, following post treatment care and attending all treatment and follow up&#xD;
             visits.&#xD;
&#xD;
          5. Has Fitzpatrick skin types I to IV.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. The subject is female and pregnant, has been pregnant within the last 3 months, is&#xD;
             currently breast feeding or planning a pregnancy during the study period.&#xD;
&#xD;
          2. The subject is hypersensitive to light exposure OR takes photo sensitized medication.&#xD;
&#xD;
          3. The subject has active or localized systemic infections.&#xD;
&#xD;
          4. The subject has a coagulation disorder or is currently using anti-coagulation&#xD;
             medication (including but not limited to heavy aspirin therapy {greater than 81 mg per&#xD;
             day}).&#xD;
&#xD;
          5. The subject has any condition which, in the investigator's opinion, would make it&#xD;
             unsafe for the subject to participate in this research study.&#xD;
&#xD;
          6. The subject is currently enrolled in an investigational drug or device trial, or has&#xD;
             received an investigational drug or been treated with an investigational device within&#xD;
             3 months prior to entering this study.&#xD;
&#xD;
          7. The subject has used Accutane within 6 months prior to enrollment.&#xD;
&#xD;
          8. The subject has the need to be exposed to artificial tanning devices or excessive&#xD;
             sunlight during the trial.&#xD;
&#xD;
          9. The subject has had prior treatment with parenteral gold therapy (gold sodium&#xD;
             thiomalate).&#xD;
&#xD;
         10. The subject has a history of keloids.&#xD;
&#xD;
         11. The subject has evidence of compromised wound healing.&#xD;
&#xD;
         12. The subject has a history of squamous cell carcinoma or melanoma.&#xD;
&#xD;
         13. The subject has a history of immunosuppression/immune deficiency disorders (including&#xD;
             HIV infection or AIDS) or use of immunosuppressive medications.&#xD;
&#xD;
         14. The subjects has an allergy to lidocaine and epinephrine.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patricia Krantz</last_name>
    <role>Study Director</role>
    <affiliation>Cynosure, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Laser &amp; Skin Surgery Center of New York</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>March 12, 2013</study_first_submitted>
  <study_first_submitted_qc>March 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2013</study_first_posted>
  <last_update_submitted>October 27, 2020</last_update_submitted>
  <last_update_submitted_qc>October 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

